Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sarepta Should Gain Clean Slate With CBER Review of DMD Gene Therapy

Executive Summary

Sarepta will face a US FDA staff with which it does not have a controversial history, the Center for Biologics Evaluation and Research, likely avoiding the reviewers that evaluated its Duchenne muscular dystrophy treatment Exondys 51.


Related Content

Gene Therapy Oversight To Be Streamlined By US FDA, NIH
Sarepta Learns Why Earlier GMP Control Is Better For Promising Gene Therapies
Familiar Principles In Gene Therapy Guidance For Rare Diseases
Refining A Controversial Endpoint: Sarepta Banking On Dystrophin Levels For Golodirsen Approval In DMD
Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure
Exondys 51’s Development: Was Placebo-Controlled Trial Possible?
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Duchenne Muscular Dystrophy: Second Product Isn't The Charm


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts